Sugi Predict

Sugi Predict / Compounds / SCHEMBL1171367

SCHEMBL1171367

SCHEMBL1171367

CN(CCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1)CC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ SLC6A9 P48067 19/20 1.00
▸ SLC6A4 P31645 1/20 0.73
▸ HRH3 Q9Y5N1 1/20 0.73
▸ ALDH1A1 P00352 1/20 0.69
▸ CYP2D6 P10635 1/20 0.69
▸ MAPT P10636 1/20 0.69
▸ CYP2C9 P11712 1/20 0.69
▸ CYP2C19 P33261 1/20 0.69
▸ SLC6A5 Q9Y345 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15127607 1.00 SLC6A9 (1.00) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
SCHEMBL6567420 0.97 SLC6A9 (0.93) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
SCHEMBL6823223 0.94 SLC6A9 (0.89) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
SCHEMBL6828424 0.93 SLC6A9 (0.86) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
SCHEMBL6254425 0.92 SLC6A9 (0.85) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
Lithium Ion SCHEMBL29612899 0.91 SLC6A9 (1.00) SLC6A9
SCHEMBL6254432 0.90 SLC6A9 (0.80) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
SCHEMBL6013413 0.89 SLC6A9 (0.80) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
SCHEMBL6257273 0.89 SLC6A9 (0.80) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6
SCHEMBL6259757 0.89 SLC6A9 (0.80) SLC6A9SLC6A4HRH3ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006034196-A1 COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR LIFELIKE BIOMATIC INC. (US) 2006-03-30 — — WO claimed
US-20060063707-A1 Compositions for enhancing memory and methods therefor LIFELIKE BIOMATIC, INC. (US) 2006-03-23 — — US claimed
EP-2288345-B1 PSYCHO-PHARMACEUTICALS UNIV DUBLIN (IE) 2015-06-10 — — EP disclosed
WO-2011067225-A1 COMPOSITIONS TARGETING CB1 RECEPTOR FOR CONTROLLING FOOD INTAKE INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2011-06-09 — — WO disclosed
EP-2288345-A1 PSYCHO-PHARMACEUTICALS University College Dublin National University Of Ireland, Dublin (IE) 2011-03-02 — — EP disclosed
US-20110034565-A1 PSYCHO-PHARMACEUTICALS UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2011-02-10 — — US disclosed
WO-2009128058-A1 PSYCHO-PHARMACEUTICALS UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al (IE) 2009-10-22 — — WO disclosed
WO-2006034196-A1 COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR LIFELIKE BIOMATIC INC. (US) 2006-03-30 — — WO disclosed
US-20060063707-A1 Compositions for enhancing memory and methods therefor LIFELIKE BIOMATIC, INC. (US) 2006-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063707-A1 Compositions for enhancing memory and methods therefor GRIN1, GRIN3A, GRIN2A SLC6A9 2144/4885SLC6A4 1017/4885HRH3 793/4885
US-20110034565-A1 PSYCHO-PHARMACEUTICALS PNMT, HTR3C, HTR5A SLC6A9 3575/4885SLC6A4 154/4885HRH3 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.